George Lundberg, MD Editor in Chief at Cancer Commons

  • December 2, 2019  

    Risk of a Second Cancer in Canadians Diagnosed with a First Cancer in Childhood or Adolescence Bookmark

    George Lundberg, MD

    Research paper from EClinicalMedicine curated by Editor in Chief George Lundberg, MD, who notes: 

    People who survive after treatment for childhood cancers have a greatly increased likelihood of developing a second cancer, with younger patients at greatest risk.

    Go to full paper published in EClinicalMedicine.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma Bookmark

    George Lundberg, MD

    Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

    The FDA has granted accelerated approval for the drug erlofitinib in advanced urothelial malignancies that meet specific criteria.

    Go to full article published by the FDA.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Deciding on the Ideal First-Line Treatment for Rare and Advanced Kidney Cancers Bookmark

    George Lundberg, MD

    Article from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    In recent clinical trials, the drug cabozantinib is being found to greatly increase progression-free survival.

    Go to full article published by Targeted Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Ovarian Cancer: Is This the Beginning of the End? Bookmark

    George Lundberg, MD

    Article from Healio curated by Editor in Chief George Lundberg, MD, who notes: 

    This piece discusses recent insights into ovarian cancer, including the fact that this type of cancer sometimes originates in the fallopian tube, and that drugs known as PARP inhibitors show great therapeutic promise.

    Go to full article published by Healio.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Novel, High-Accuracy Blood Test Can Screen for Multiple Cancers Bookmark

    George Lundberg, MD

    Article from MDLinx curated by Editor in Chief George Lundberg, MD, who notes: 

    Very early detection of potentially lethal cancer remains an elusive goal. Blood tests that evaluate methylation of cell-free DNA may be one strategy for earlier detection of ovarian cancer and other types of cancer. High sensitivity and specificity are crucial.

    Go to full article published by MDLinx.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Scientists Find Promising Drug Combination Against Lethal Childhood Brain Cancers Bookmark

    George Lundberg, MD

    Article from EurekAlert curated by Editor in Chief George Lundberg, MD, who notes: 

    Researchers have shown that a combination therapy is effective against cancer cells in test-tube experiments and laboratory animals. It has not yet been tested in humans.

    Go to full article published by EurekAlert.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Nivolumab Versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (Attraction-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial Bookmark

    George Lundberg, MD

    Research paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes: 

    In this clinical trial, nivolumab was somewhat superior to chemotherapy for advanced esophageal carcinoma.

    Go to full paper published in The Lancet.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In an unusual collaboration between the U.S. Food and Drug Administration (FDA), Canada, and Australia, acalabrutinib (Calquence) has been approved as another first line therapy for chronic lymphatic leukemia/small cell lymphoma.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    FDA Approves Therapy to Treat Patients with Relapsed and Refractory Mantle Cell Lymphoma Supported by Clinical Trial Results Showing High Response Rate of Tumor Shrinkage Bookmark

    George Lundberg, MD

    Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

    Of the non-Hodgkin lymphomas, mantle cell lymphoma can be especially difficult to treat. The FDA has now announced accelerated approval for the drug zanubrutinib (Brukinsa) after it showed strong effects for patient in single-arm clinical trials.

    Go to full article published by the U.S. Food and Drug Administration (FDA).

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Biological Activity of Weekly ONC201 in Adult Recurrent Glioblastoma Patients Bookmark

    George Lundberg, MD

    Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    This paper reports the results of an investigation of the drug ONC201 in adults with recurrent glioblastoma (GBM). It found that ONC201 penetrated the blood-brain barrier and achieved intratumoral levels without toxicity. While most GBMs were not responsive, one patient with the mutation H3 K27M experienced a prolonged remission.

    Go to full paper published in Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.